Phase 3 Clinical Trials With Primary Completion Dates in April 2021
This is a list of Phase 3 trials with primary completion dates in April 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| EIGR | Eiger BioPharmaceuticals, Inc. | 2021-04-01 | Phase 3 | NCT03719313 | Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a |
| MDXG | MiMedx Group, Inc. | 2021-04-01 | Phase 3 | NCT03414268 | Micronized dHACM Injectable for the Treatment of Plantar Fasciitis |
| OPTN | OptiNose, Inc. | 2021-04-01 | Phase 3 | NCT03960580 | Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps |
| SLNO | Soleno Therapeutics, Inc. | 2021-04-01 | Phase 3 | NCT03714373 | Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome |